Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CTGF
REST API REST API
Homo sapiens
CTGF is differentially expressed in 276 experiments: 144 organism parts: liver, cerebellum, ... (142 more);, 206 disease states: normal, glioblastoma, ... (204 more);, 91 cell types 453 cell lines 32 compound treatments and 54 other conditions.
Synonyms IGFBP8, CCN2
Orthologs CTGF_BOVIN (Bos taurus)   CTGF (Gallus gallus)   Ctgf (Rattus norvegicus)   Ctgf (Mus musculus)   ENSCING00000006564 (Ciona intestinalis)   ENSCING00000006772 (Ciona intestinalis)   ctgf (Danio rerio)   ENSCING00000006549 (Ciona intestinalis)   ENSCING00000005383 (Ciona intestinalis)   Ccn (Drosophila melanogaster)   ctgf (Xenopus laevis)   CTGF (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, positive regulation of caspase activity, cis-Golgi network, protein binding, response to wounding, cell cortex, extracellular space, positive regulation of cell proliferation, positive regulation of gene expression, heparin binding, proteinaceous extracellular matrix, growth factor activity, extracellular region, insulin-like growth factor binding, cell adhesion, epidermis development, regulation of cell growth, perinuclear region of cytoplasm, DNA replication, response to mineralocorticoid stimulus, positive regulation of collagen biosynthetic process, organ senescence, positive regulation of cardiac muscle contraction, positive regulation of cell death, response to fatty acid, response to amino acid stimulus, response to peptide hormone stimulus, response to estradiol stimulus, lung development, positive regulation of cell activation, response to glucose stimulus, cellular lipid metabolic process, positive regulation of G0 to G1 transition, cytosolic calcium ion transport, extracellular matrix constituent secretion, response to anoxia, fibronectin binding, intracellular signal transduction, positive regulation of protein phosphorylation, response to organic cyclic compound
InterPro Term Cys_knot_C, VWF_C, Thrombospondin_1_rpt, IGFBP-like, Cys_knot, IGFBP_CNN
UniProt Accession P29279, B3KWK5
Search EB-eye ENSG00000118523
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-4717, E-MTAB-62, ... (36 experiments)

Factor Value U/D Experiments
LNCaP
2
E-GEOD-14464, E-GEOD-14990
HCC1143
2
E-MTAB-37, E-MTAB-62
HL-60
2
E-GEOD-5258, E-MTAB-37
Jurkat
2
E-GEOD-1880, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MOLT4
2
E-MTAB-37, E-MTAB-62
447 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, ... (44 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-MEXP-2034, E-GEOD-1460, E-MEXP-1327, E-MEXP-1121
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
ovarian cancer
1
E-GEOD-21154
parental foreskin cells
1
E-GEOD-20033
LCC
1
E-GEOD-19188
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (54 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4290
prostate carcinoma
4
E-MTAB-62, E-GEOD-96, E-GEOD-3868, E-MEXP-2034
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-62, E-MTAB-37
uterine fibroid
3
E-MTAB-62, E-GEOD-2724, E-GEOD-7307
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-3868
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
200 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
sapphyrin PCI-2053
1
E-GEOD-6400
Cxcl12
1
E-GEOD-7307
sapphyrin PCI-2055
1
E-GEOD-6400
insulin
1
E-GEOD-22309
TTA
1
E-MEXP-2590
26 more value(s).


Biosource provider

studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

Factor Value U/D Experiments
Provitro GmbH, Berlin, Germany
1
E-GEOD-14359
Discordant twin
1
E-TABM-325
Charite Universitätsmedizin Berlin
1
E-GEOD-14359
DSMZ
1
E-MTAB-37
StThomas twins
1
E-TABM-325


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-19348, E-GEOD-994, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2283, E-MEXP-958, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-1235, E-GEOD-2292, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-10315, E-TABM-440, E-GEOD-837, E-GEOD-1692, E-MEXP-1273, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1956, E-GEOD-1926, E-TABM-118, ... (26 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-MEXP-561, E-GEOD-6802

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-20037

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-548, ... (8 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-147

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.549 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM